Table 2.

TEAEs by treatment

	Vericiguat + sildenafil (n = 16)	Placebo + sildenafil (n = 16)	Total (N = 32)
Number (%) with at least one TEAE	16 (100.0)	7 (43.8)	23 (71.9)
Vericiguat-related TEAE	10 (62.5)	1 (6.3)	11 (34.4)
Sildenafil-related TEAE	14 (87.5)	6 (37.5)	20 (62.5)
Maximum TEAE intensity
Mild	13 (81.3)	7 (43.8)	20 (62.5)
Moderate	3 (18.8)	0	3 (9.4)
Maximum intensity of vericiguat-related TEAE
Mild	7 (43.8)	1 (6.3)	8 (25.0)
Moderate	3 (18.8)	0	3 (9.4)
Maximum intensity of sildenafil-related TEAE
Mild	11 (68.8)	6 (37.5)	17 (53.1)
Moderate	3 (18.8)	0	3 (9.4)
Discontinuation of vericiguat due to AE	1 (6.3)	0	1 (3.1)
Discontinuation of sildenafil due to AE	1 (6.3)	0	1 (3.1)

AE adverse event, TEAE treatment-emergent adverse event